Kathleen E. Rodgers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kathleen E. Rodgers has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
G S Dizerega
3 shared publicationsGere S. Dizerega
University of Southern California, Keck School of Medicine, 1321 N. Mission Road, Los Angeles, CA 90033, USA
2 shared publications- Gere S. Dizerega
US Biotest, Inc., San Luis Obispo, CA, USA
2 shared publications Joseph D. Campeau
2 shared publicationsNorma Roda
Keck School of Medicine, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA
2 shared publicationsSonia Maldonado
Keck School of Medicine, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA
2 shared publications
Latest Publications
- 10 December 2003
- Published by Wiley in Experimental Dermatology
- Vol. 12 (6) , 784-790
Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice
Abstract: Recent studies have shown that angiotensin peptides accelerate dermal repair. Histological observation of samples taken at the termination of studies showed that the wounds treated with peptides were more mature and organized by day 25 after full thickness excision in diabetic mice. However, the mechanism by which this acceleration occurs has not been determined. In the experiments described here, the effect of angiotensin peptides [AII, A(1–7) and NorLeu3‐A(1–7)] on the quality of the healing wound was evaluated histologically. Administration of the peptides accelerated collagen deposition, re‐epithelialization and new blood vessel formation. By day 4, the percentage of the wound with collagen increased two‐ to six‐fold depending upon the peptide. The increase by angiotensin peptides continued throughout the experimental period. On days 4 and 7 (only) after injury, exposure to angiotensin peptides increased the number of blood vessels at the wound site two‐ to three‐fold. Finally, the percentage of the wound site covered with new epithelium increased after administration of angiotensin peptides. Re‐epithelialization was observed as early as day 4 in wounds treated with angiotensin peptides. The increase was greater at later time points [up to 8‐fold at day 14 with NorLeu3‐A(1–7)]. Fibroblast infiltration and proliferation occurred earlier in wounds treated with angiotensin peptides. Wounds treated with A(1–7) and NorLeu3‐A(1–7) had an increase in neutrophils and macrophages on day 4 after wounding. Overall, administration of these peptides resulted in a healing site that was more mature, including reorganization of the collagen into a basket‐weave appearance. Further, these studies confirm the superiority of NorLeu3‐A(1–7) to AII and A(1–7) in wound healing evaluated at a microscopic level.
- 10 December 2003
- Published by Wiley in Experimental Dermatology
- Vol. 12 (6) , 784-790
Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice
Abstract: Recent studies have shown that angiotensin peptides accelerate dermal repair. Histological observation of samples taken at the termination of studies showed that the wounds treated with peptides were more mature and organized by day 25 after full thickness excision in diabetic mice. However, the mechanism by which this acceleration occurs has not been determined. In the experiments described here, the effect of angiotensin peptides [AII, A(1–7) and NorLeu3‐A(1–7)] on the quality of the healing wound was evaluated histologically. Administration of the peptides accelerated collagen deposition, re‐epithelialization and new blood vessel formation. By day 4, the percentage of the wound with collagen increased two‐ to six‐fold depending upon the peptide. The increase by angiotensin peptides continued throughout the experimental period. On days 4 and 7 (only) after injury, exposure to angiotensin peptides increased the number of blood vessels at the wound site two‐ to three‐fold. Finally, the percentage of the wound site covered with new epithelium increased after administration of angiotensin peptides. Re‐epithelialization was observed as early as day 4 in wounds treated with angiotensin peptides. The increase was greater at later time points [up to 8‐fold at day 14 with NorLeu3‐A(1–7)]. Fibroblast infiltration and proliferation occurred earlier in wounds treated with angiotensin peptides. Wounds treated with A(1–7) and NorLeu3‐A(1–7) had an increase in neutrophils and macrophages on day 4 after wounding. Overall, administration of these peptides resulted in a healing site that was more mature, including reorganization of the collagen into a basket‐weave appearance. Further, these studies confirm the superiority of NorLeu3‐A(1–7) to AII and A(1–7) in wound healing evaluated at a microscopic level.
- 1 May 2002
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 49 (5) , 403-411
Accelerated recovery from irradiation injury by angiotensin peptides
Purpose: Angiotensin peptides have been shown to affect the proliferation and chemotaxis of multiple cell types. More recent studies in this laboratory have shown that angiotensin II (AII) can increase colony formation and proliferation by hematopoietic progenitors and mesenchymal cells in vitro. As white blood cell (WBC) recovery after bone marrow injury requires progenitor proliferation, the effect of AII and angiotensin (1–7) [A(1–7)], a non-hypertensive fragment of AII, on recovery from total body irradiation was evaluated in C57Bl/6 mice. Materials and methods: The effect of angiotensin peptides on hematopoietic recovery and the number of progenitors in the bone marrow of irradiated C57Bl/6 mice was evaluated. Results: Treatment of animals with angiotensin peptides accelerated hematopoietic recovery and increased the number of hematopoietic progenitors in bone marrow and in the blood. The increase in WBC concentration continued for a longer time after cessation of AII therapy than after treatment with filgrastim. Specifically, the number of WBCs continued to increase 21 days after irradiation with 7 days of angiotensin peptide administration. In contrast, the number of WBCs increased through day 13 with 7 days of filgrastim administration. On day 35 after irradiation (28 days after the last treatment), AII was shown to have increased the number of CFU-GM in the bone marrow of irradiated mice, whereas filgrastim administration had not. Angiotensin peptides also reduced the drop in platelet concentration after irradiation and increased the number of megakaryocyte precursors and megakaryocytes in the bone marrow. Receptor blocking studies indicated that losartan, an antagonist of the angiotensin type 1 receptor, blocked recovery of WBC levels in response to treatment with AII. In contrast, the increase in WBC levels in response to treatment with A(1–7), a ligand for other angiotensin receptors, was not affected by losartan. Conclusions: These findings suggest that these peptides utilize distinct receptors in the stimulation of hematopoietic recovery. In summary, systemic administration of angiotensin peptides led to an acceleration in hematopoietic recovery after irradiation. These peptides act to stimulate the formation of bone marrow progenitors, thereby facilitating recovery after myelosuppressive irradiation.
- 1 May 2002
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 49 (5) , 403-411
Accelerated recovery from irradiation injury by angiotensin peptides
Purpose: Angiotensin peptides have been shown to affect the proliferation and chemotaxis of multiple cell types. More recent studies in this laboratory have shown that angiotensin II (AII) can increase colony formation and proliferation by hematopoietic progenitors and mesenchymal cells in vitro. As white blood cell (WBC) recovery after bone marrow injury requires progenitor proliferation, the effect of AII and angiotensin (1–7) [A(1–7)], a non-hypertensive fragment of AII, on recovery from total body irradiation was evaluated in C57Bl/6 mice. Materials and methods: The effect of angiotensin peptides on hematopoietic recovery and the number of progenitors in the bone marrow of irradiated C57Bl/6 mice was evaluated. Results: Treatment of animals with angiotensin peptides accelerated hematopoietic recovery and increased the number of hematopoietic progenitors in bone marrow and in the blood. The increase in WBC concentration continued for a longer time after cessation of AII therapy than after treatment with filgrastim. Specifically, the number of WBCs continued to increase 21 days after irradiation with 7 days of angiotensin peptide administration. In contrast, the number of WBCs increased through day 13 with 7 days of filgrastim administration. On day 35 after irradiation (28 days after the last treatment), AII was shown to have increased the number of CFU-GM in the bone marrow of irradiated mice, whereas filgrastim administration had not. Angiotensin peptides also reduced the drop in platelet concentration after irradiation and increased the number of megakaryocyte precursors and megakaryocytes in the bone marrow. Receptor blocking studies indicated that losartan, an antagonist of the angiotensin type 1 receptor, blocked recovery of WBC levels in response to treatment with AII. In contrast, the increase in WBC levels in response to treatment with A(1–7), a ligand for other angiotensin receptors, was not affected by losartan. Conclusions: These findings suggest that these peptides utilize distinct receptors in the stimulation of hematopoietic recovery. In summary, systemic administration of angiotensin peptides led to an acceleration in hematopoietic recovery after irradiation. These peptides act to stimulate the formation of bone marrow progenitors, thereby facilitating recovery after myelosuppressive irradiation.
- Open Access
- 1 July 2000
- Published by American Society for Microbiology in Clinical and Diagnostic Laboratory Immunology
- Vol. 7 (4) , 635-640
Angiotensin II Increases Host Resistance to Peritonitis
Studies by other laboratories have shown that angiotensin II (AII) can affect the function of cells which comprise the immune system. In the present study, the effect of AII on the function of peritoneal macrophages and peripheral blood monocytes was assessed. In vitro exposure (4 h prior to assay) of peritoneal macrophages from mice and rats to AII increased the percentage of cells that phagocytosed opsonized yeast and the number of yeast per macrophage. Furthermore, AII increased the respiratory burst capacity of peritoneal macrophages from mice and rats and peripheral blood mononuclear cells from humans. Because of these observations, the effect of AII on host resistance to bacterial infection was assessed. Intraperitoneal administration of AII was shown to increase host resistance (reduced abscess formation) in an animal model of bacterial peritonitis. Studies were then conducted to assess whether parenteral administration of AII, a clinically relevant route, could affect peritoneal host resistance in a manner similar to that observed after peritoneal administration. These studies showed that subcutaneous administration of AII throughout the postinfection interval increased the level of host resistance to bacterial peritonitis. Furthermore, in a study which compared AII and Neupogen, an agent approved for use for the reduction of febrile neutropenia after myeloablative therapy, daily subcutaneous administration of AII reduced abscess size and incidence, whereas Neupogen did not have any therapeutic benefit in this model. These data suggest that AII may be of therapeutic benefit as an immunomodulatory agent.
- 1 July 2000
- Published by American Society for Microbiology in Clinical and Diagnostic Laboratory Immunology
- Vol. 7 (4) , 635-640
Open AccessAngiotensin II Increases Host Resistance to Peritonitis
Studies by other laboratories have shown that angiotensin II (AII) can affect the function of cells which comprise the immune system. In the present study, the effect of AII on the function of peritoneal macrophages and peripheral blood monocytes was assessed. In vitro exposure (4 h prior to assay) of peritoneal macrophages from mice and rats to AII increased the percentage of cells that phagocytosed opsonized yeast and the number of yeast per macrophage. Furthermore, AII increased the respiratory burst capacity of peritoneal macrophages from mice and rats and peripheral blood mononuclear cells from humans. Because of these observations, the effect of AII on host resistance to bacterial infection was assessed. Intraperitoneal administration of AII was shown to increase host resistance (reduced abscess formation) in an animal model of bacterial peritonitis. Studies were then conducted to assess whether parenteral administration of AII, a clinically relevant route, could affect peritoneal host resistance in a manner similar to that observed after peritoneal administration. These studies showed that subcutaneous administration of AII throughout the postinfection interval increased the level of host resistance to bacterial peritonitis. Furthermore, in a study which compared AII and Neupogen, an agent approved for use for the reduction of febrile neutropenia after myeloablative therapy, daily subcutaneous administration of AII reduced abscess size and incidence, whereas Neupogen did not have any therapeutic benefit in this model. These data suggest that AII may be of therapeutic benefit as an immunomodulatory agent.
- Open Access
- 1 July 2000
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 18 (4) , 287-294
Effect of Angiotensin II on Hematopoietic Progenitor Cell Proliferation
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.
- 1 July 2000
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 18 (4) , 287-294
Open AccessEffect of Angiotensin II on Hematopoietic Progenitor Cell Proliferation
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.
- 19 September 1997
- Published by Elsevier in Toxicology Letters
- Vol. 93 (1) , 73-82
Effect of administration of malathion for 90 days on macrophage function and mast cell degranulation
- 19 September 1997
- Published by Elsevier in Toxicology Letters
- Vol. 93 (1) , 73-82
Effect of administration of malathion for 90 days on macrophage function and mast cell degranulation
- 1 June 1997
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 12 (Suppl_2) , 336-337
R-235. Comparison of REPEL™ and INTERCEED™ in the reduction of adhesion formation in the presence of blood in rabbit models
- 1 June 1997
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 12 (Suppl_2) , 336-337
R-235. Comparison of REPEL™ and INTERCEED™ in the reduction of adhesion formation in the presence of blood in rabbit models
- 1 January 1996
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 9 (6) , 447-453
Alterations of Angiotensin II Receptor Levels in Sutured Wounds in Rat Skin
Angiotensin II receptor levels have been shown to vary with postoperative time in tissue harvested from full-thickness dermal excisional wounds on adult rats. This study examined the expression of AII receptors in a sutured wound model. Two full-thickness incisional wounds were made in the dorsal skin of adult Sprague-Dawley rats and sutured immediately under general anesthesia. The wound tissues were harvested at 0, 0.5, 1, 2, 4, 24 h and on days 2, 3, 4, 5, 7, and 10 after the wounding. The levels of 125I-Sar1.Ile8-AII bound to membrane preparations of the wound tissues decreased at early time points (from 0.5 to 4 h), increased from day 1 to day 7, and returned to nonsurgical levels by day 10. Competitive binding studies showed that the receptors were predominantly of the AT1 receptor subtype. These results suggest that an immediate and transient reduction in AII receptor expression occurred after wounding, followed by an increase in the number of AII receptors that was maintained for 5 to 7 days postoperatively. Because these data are consistent with those observed after excisional wounding, temporal changes in AII receptor expression may be integral to the process of wound healing.
- 1 January 1996
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 9 (6) , 447-453
Alterations of Angiotensin II Receptor Levels in Sutured Wounds in Rat Skin
Angiotensin II receptor levels have been shown to vary with postoperative time in tissue harvested from full-thickness dermal excisional wounds on adult rats. This study examined the expression of AII receptors in a sutured wound model. Two full-thickness incisional wounds were made in the dorsal skin of adult Sprague-Dawley rats and sutured immediately under general anesthesia. The wound tissues were harvested at 0, 0.5, 1, 2, 4, 24 h and on days 2, 3, 4, 5, 7, and 10 after the wounding. The levels of 125I-Sar1.Ile8-AII bound to membrane preparations of the wound tissues decreased at early time points (from 0.5 to 4 h), increased from day 1 to day 7, and returned to nonsurgical levels by day 10. Competitive binding studies showed that the receptors were predominantly of the AT1 receptor subtype. These results suggest that an immediate and transient reduction in AII receptor expression occurred after wounding, followed by an increase in the number of AII receptors that was maintained for 5 to 7 days postoperatively. Because these data are consistent with those observed after excisional wounding, temporal changes in AII receptor expression may be integral to the process of wound healing.
- 1 November 1994
- Vol. 7 (6)
Time-dependent effect of tolmetin sodium in a rabbit uterine adhesion model.
- 1 November 1994
- Vol. 7 (6)
Time-dependent effect of tolmetin sodium in a rabbit uterine adhesion model.
- 1 July 1992
- Vol. 36, 248-57
Protease and protease inhibitor secretion by postsurgical macrophages following in vitro exposure to tolmetin.
Tolmetin sodium was shown previously to reduce the level of adhesions formed after peritoneal surgery. In addition, when tolmetin was administered to rats at the time of surgery, the level of macrophage activity (phagocytosis, superoxide anion production and tumoricidal activity) was elevated. In this study, the level of neutral protease activity in the culture supernatant of peritoneal macrophages from postsurgical rabbits. after in vitro exposure to tolmetin was examined. The level of collagenase, elastase and plasminogen activator inhibitor activity in the culture supernatant of macrophages was modulated after peritoneal surgery. Collagenase activity in the culture supernatant of macrophages from nonsurgical and postsurgical rabbits up to 48 h was reduced after co-culture with tolmetin. In contrast, elastase secretion was elevated to maximal levels (which plateaued 24 h after surgery in cultures of control macrophages) in cultures of macrophages from nonsurgical and early postsurgical (6 and 12 h) rabbits by in vitro exposure to tolmetin. Alternatively, the level of plasminogen activator inhibitor activity in the culture supernatants of postsurgical macrophages was reduced after in vitro exposure to tolmetin. These data indicate that tolmetin, a nonsteroidal anti-inflammatory agent, modulates the levels of collagenase, elastase and plasminogen activator inhibitor activity in culture supernatants of postsurgical macrophages.
- 1 July 1992
- Vol. 36, 248-57
Protease and protease inhibitor secretion by postsurgical macrophages following in vitro exposure to tolmetin.
Tolmetin sodium was shown previously to reduce the level of adhesions formed after peritoneal surgery. In addition, when tolmetin was administered to rats at the time of surgery, the level of macrophage activity (phagocytosis, superoxide anion production and tumoricidal activity) was elevated. In this study, the level of neutral protease activity in the culture supernatant of peritoneal macrophages from postsurgical rabbits. after in vitro exposure to tolmetin was examined. The level of collagenase, elastase and plasminogen activator inhibitor activity in the culture supernatant of macrophages was modulated after peritoneal surgery. Collagenase activity in the culture supernatant of macrophages from nonsurgical and postsurgical rabbits up to 48 h was reduced after co-culture with tolmetin. In contrast, elastase secretion was elevated to maximal levels (which plateaued 24 h after surgery in cultures of control macrophages) in cultures of macrophages from nonsurgical and early postsurgical (6 and 12 h) rabbits by in vitro exposure to tolmetin. Alternatively, the level of plasminogen activator inhibitor activity in the culture supernatants of postsurgical macrophages was reduced after in vitro exposure to tolmetin. These data indicate that tolmetin, a nonsteroidal anti-inflammatory agent, modulates the levels of collagenase, elastase and plasminogen activator inhibitor activity in culture supernatants of postsurgical macrophages.
- 1 January 1992
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 5 (4) , 285-296
In Vivo Administration of Tolmetin in Hyaluronic Acid Modulates Protease Levels in Postsurgical Macrophage-Conditioned Media
Tolmetin sodium in a hyaluronic acid carrier (tolmetin-HA) was previously shown to reduce adhesion formation and alter the kinetics and levels of cellular influx into the peritoneal cavity after surgery. In this study, the effect of tolmetin-HA on the level of protease activity in macrophage-conditioned media was determined. The level of collagenase activity in macrophage-conditioned media was suppressed at 12 and 24 h after administration of tolmetin-HA. Alternatively, the peak level of elastase activity measured in macrophage-conditioned media was unchanged after tolmetin-HA treatment, but the kinetics of expression of maximal protease activity was delayed from 12 h in the control surgical rabbits to 24 h in tolmetin-HA-treated rabbits. Elevated plasminogen activator activity was detected in acid-treated conditioned media from the tolmetin-HA-treated rabbits when compared to control levels. However, no alteration in the level of plasminogen activator inhibitor activity was present in conditioned media of macrophages harvested from tolmetin-HA-treated rabbits compared to controls. These data suggest that tolmetin-HA treatment altered the levels of neutral protease activity secreted by postsurgical macrophages and may therefore elevate the fibrinolytic potential of the peritoneal cavity after surgery.
- 1 January 1992
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 5 (4) , 285-296
In Vivo Administration of Tolmetin in Hyaluronic Acid Modulates Protease Levels in Postsurgical Macrophage-Conditioned Media
Tolmetin sodium in a hyaluronic acid carrier (tolmetin-HA) was previously shown to reduce adhesion formation and alter the kinetics and levels of cellular influx into the peritoneal cavity after surgery. In this study, the effect of tolmetin-HA on the level of protease activity in macrophage-conditioned media was determined. The level of collagenase activity in macrophage-conditioned media was suppressed at 12 and 24 h after administration of tolmetin-HA. Alternatively, the peak level of elastase activity measured in macrophage-conditioned media was unchanged after tolmetin-HA treatment, but the kinetics of expression of maximal protease activity was delayed from 12 h in the control surgical rabbits to 24 h in tolmetin-HA-treated rabbits. Elevated plasminogen activator activity was detected in acid-treated conditioned media from the tolmetin-HA-treated rabbits when compared to control levels. However, no alteration in the level of plasminogen activator inhibitor activity was present in conditioned media of macrophages harvested from tolmetin-HA-treated rabbits compared to controls. These data suggest that tolmetin-HA treatment altered the levels of neutral protease activity secreted by postsurgical macrophages and may therefore elevate the fibrinolytic potential of the peritoneal cavity after surgery.